Evolva SA Agrees to Reverse Merger with Arpida
9/11/2009 8:43:50 AM
More...
|
Arpida to Discuss Strategy With Shareholders
5/7/2009 11:48:23 AM
More...
|
Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5/7/2009 11:16:34 AM
More...
|
Arpida Board Reviews Strategic Options to Present to Shareholders at Shareholders' Meeting
3/17/2009 10:33:06 AM
More...
|
Arpida Announces Full Year 2008 Financial Results
2/25/2009 11:26:00 AM
More...
|
FDA Issues Arpida Complete Response Letter for Iclaprim
1/20/2009 8:30:25 AM
More...
|
Arpida Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee Meeting on iclaprim
11/18/2008 10:06:28 AM
More...
|
Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
10/27/2008 10:33:35 AM
More...
|
Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
10/15/2008 11:48:58 AM
More...
|
Arpida Completes Enrollment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
9/24/2008 11:21:43 AM
More...
|
|